SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla declines on recalling 1.40 lakh vials of Levalbuterol Inhalation Solution in US

22 May 2015 Evaluate

Cipla is currently trading at Rs. 673.50, down by 0.90 points or 0.13% from its previous closing of Rs. 674.40 on the BSE.

The scrip opened at Rs. 676.00 and has touched a high and low of Rs. 680.00 and Rs. 667.40 respectively. So far 59870 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 368.70 on 30-May-2014.

Last one week high and low of the scrip stood at Rs. 694.00 and Rs. 669.50 respectively. The current market cap of the company is Rs. 54019.16 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 35.18% and 25.83% respectively.

Cipla is recalling in the US market 1,40,625 vials of Levalbuterol Inhalation Solution used for relieving shortness of breath and coughing caused by asthma and chronic obstructive pulmonary disease. The drug major is recalling the drug for ‘failed impurities and degradation specifications’.

The vials were manufactured by Cipla at its Pithampur manufacturing facility, near Indore, for Princeton-based Dr Reddy's Laboratories Inc. The nationwide recall has been initiated by the company on April 24 this year.

The recall of the drugs has been initiated under Class-III which FDA defined as ‘a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences’.

Cipla, which has presence in over 150 countries, sells more than 2,000 products across various therapeutic categories. The company has 34 manufacturing facilities that make active pharmaceutical ingredients (APIs) and formulations.

Cipla Share Price

1232.80 -5.50 (-0.44%)
20-Apr-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.35
Dr. Reddys Lab 1236.85
Cipla 1232.80
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×